Private biopharmaceutical companies raised more than $1bn from venture capital, seed financing and government investments during the past week, including Eliem Therapeutics, Inc., which said on 24 May that it closed a $60m series B round just two months after it launched with $80m in VC funding.
Eliem’s $140m in combined financing during such a short span of time gives the company venture capital mega-round status at...







